Valimed

[Viking65]

This message board is about Valimed.
Take it somewhere else please.
Thank you. Viking65

[lmorovan]

doyourdd, as I said, what I feel or think is what I feel and think, whether you believe it or not. And nothing you say or do will change it. So, you either learn to live with it or embarrass yourself. Your choice.

[doyourdd]

Loch could not run an Ice Cream truck, We all know that. Now we all have a very good chance of making something from our investment. Stop your BS that you only want to help ex loch investors. I will not feed your suply.

[doyourdd]

INET; Sorry that was the wrong board I gave you.. Its on the new cdex board on Ragingbull mesg 195.. I Really believe L.Morovan has a personality Disorder. A narcissist's have a super ego.They have Grandiose fantasies, ie, He becomes a member of the BOD of Cdex. I knew I had read that somewhere, Start reading @ 194, and you will see how he twists and lies. From What I understand He then offered his help to cdex and was rejected. He even went so far to contact the CEOs Paster. http://www.suite101.com/article.cfm/npd/118680 I Think new investors will pick up on his BS..

[lmorovan]

doyourdd, perhaps you might consider telling the truth, for a change. Like, I was never rejected by CDEX for one reason: I never asked CDEX to be on the BOD. I suggested it to the shareholders.

So, there is nothing to be bitter about other than the fact that so far, CDEX has done NOTHING for the ex Loch shareholders. That is, NOTHING. And yes, it has done a LOT for the benefit of insiders and management itself. that is, a LOT.

On the other hand, if I wanted to be on the BOD of CDEX was to help out the shareholders, grossly ignored, abused and lied to by the management, not to help out the company. I have no qualifications in any of the fields CDEX is moving in, but I have morals, ethics and a strong heart for the good of ex Loch shareholders.

Whether you believe it or not it changes not what I feel and want for the long suffering shareholders. You can call me a paid basher or anything you want, you are wrong for the simple reason that you accuse me without any proof. I am open to any agency, bureau, departments or persons to investigate me, my life, my finances, my trading records, my phone, my on line activities, anything. But not anyone of you will ever move a finger to discover the truth, because you all know how embarrassed will you be when all of your accusations are proven wrong and ill willed. Of course, it's easier to throw out false testimony and accusations, it helps you shift the blame for your unfortunate investment, from those who are directly responsible, to me.

[doyourdd]

Oh That post. I think it is because he wanted to be on the BOD ond help cdex out, and they rejected him.. Very bitter guy. So IMHO be became a paid basher, to destroy cdex, and for the money. Its on the lochlong board about him..

[doyourdd]

What post about Elmo?

[INET6]

It is so inconsequential there is no reason to bring it up, except to bash.

5000 shares, BIIIIG DEAL.

[INET6]

It is so inconsequential there is no reason to bring it up, except to bash. 5000 shares, BIIIIG DEAL.

[INET6]

doyourdd Please tell me. How long did it take you to write that explanation of Elmo's reason for living, on these boards.
Can he really be protecting his 133 shares?

[lmorovan]

What's to bash about a SEC filing? Read my post again.

[doyourdd]

Elmo bashes CDEX again http://www.messageboardfools.com/bashers.htm

[lmorovan]

MP files another Form 4, for 5,000 more shares.

[doyourdd]

Read griffins bio see what he has done in the past. MP has taken us this far Thank-You MP. Now we will watch Griffin in action. http://www.cdex-inc.com/biogriffin.html IMO todays trading was MMs games to shake.. Stay strong

[charlie02356]

NEWS! Griffin appointed CEO

CDEX, Inc. Appoints James O. Griffin as Chief Executive Officer
Tuesday January 3, 12:34 pm ET
New CEO to Lead Company's Growth Strategy in the Healthcare, Homeland Security, Law Enforcement, and Brand Protection Markets


ROCKVILLE, Md.--(BUSINESS WIRE)--Jan. 3, 2006--CDEX Inc. (OTCBB:CEXI - News), the developer of innovative systems for substance detection and verification, announced that James O. Griffin has been named Chief Executive Officer, effective January 1, 2006. Mr. Griffin, who joined CDEX in 2005 as Chief Operating Officer, succeeds Malcolm H. Philips, who will continue as Chairman of the CDEX Board. CDEX (www.cdex-inc.com) is the developer of the ValiMed(TM) Medication Validation System, distributed by the Baxa Corporation and used by hospital pharmacies to improve patient safety and reduce medication error rates by validating compounded doses of high risk medications. Mr. Griffin, who has an extensive background in developing technology companies in the security industry, will lead the CDEX expansion of its product suite, the company's entrance into new markets, and the establishment of funding initiatives.

"I look forward to leading the CDEX team as the company strengthens its position in existing markets, expands its product offerings, and leverages its core technologies for new applications in markets such as homeland security, law enforcement, and brand protection," said James O. Griffin, CEO of CDEX, Inc. "CDEX is fortunate to have a winning combination of strong technologies, highly talented, creative, and devoted personnel, and a loyal investment community. Our vision at CDEX is to save and protect lives, property, and assets through the innovative application of technology for the betterment of society. Bringing this vision to life by building upon the foundation that has been laid by the original founders and investors, and all of the staff at CDEX is a tremendous opportunity and privilege for me."

Prior to joining CDEX, Mr. Griffin served in senior executive positions in both public and private enterprises, including Cernium, Inc., a leading developer of intelligent video analytics systems, and the IPIX Corporation, where he launched IPIX Security, the company's video surveillance division. Altogether, Mr. Griffin has more than 25 years of experience in the high technology security and defense electronic systems industries.

CDEX proprietary technologies enable real-time verification of substances through a process that utilizes a discrete energy source to produce unique return photon signatures to authenticate or validate the substance in question, such as pharmaceuticals, illegal drugs, explosives, distilled spirits, etc. CDEX technologies have applications in a number of fields, including healthcare, where it is being employed to reduce medication error rates, and to reduce the theft of pharmaceutical narcotics. CDEX recently demonstrated its ValiMed(TM) System's anti-counterfeiting capabilities at the annual mid-year meeting of the American Society of Health-Systems Pharmacists (Las Vegas, December 4-8, 2005), validating authentic Tamiflu and influenza vaccines and distinguishing these from counterfeit products in seconds using the ValiMed field-portable instrument.

In November 2005, Baxa Corporation, a leading medical device company with relationships with thousands of healthcare institutions, signed a strategic distribution agreement and made a significant investment in CDEX to secure the exclusive distribution rights for the CDEX ValiMed System for healthcare organizations in the United States and Canada. ValiMed is currently the chosen solution of a number of leading healthcare organizations, including the University of Maryland Health Center, the University of Michigan Health System, Texas Children's Hospital, and the Maricopa Medical Center.

Under Mr. Griffin's leadership, CDEX will begin implementation of its growth strategy that includes enlarging the company's intellectual property portfolio, expanding research and development capabilities, accelerating the development and launch of new products, expansion of sales channels, entering selected international markets, setting up strategic business alliances for product development, manufacturing, and service and raising capital for the acquisition of new technologies.

"Jim Griffin's vision and growth strategy for CDEX is fully supported by the CDEX Board of Directors," said Malcolm Philips, Chairman of the CDEX Board. "We have been pleased to have Jim at CDEX as our COO, and look forward to his leadership as CEO."

About CDEX, Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.

Any statements made in this press release, which contain information that is not historical, are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

Contact:
CDEX, Inc., Rockville
Media Contact:
Brad Wills, 301-346-7398
[e-mail]

http://biz.yahoo.com/bw/060103/20060103005522.html?.v=1

[INET6]

Transferred from another board compliments of butterflyfl
It looks like ValiMed may be moving into a gold mine,according to these figures.

A unit the size of three refrigerators strapped together,to mix ,yet still makes mistakes, $640,000
Feb 2004
Hospitals take aim at errors


Millions spent to avoid medication mistakes

By Tim Bonfield
The Cincinnati Enquirer
At Bethesda North Hospital, nurses are training to use a $3.8 million system that runs IV medications through a machine that looks like a bank of oversized calculators.


Rhonda Wilson, RN, a nurse manager in the Telemetry unit at Good Samaritan Hospital, checks out the Medley Medication Safety System, an intravenous delivery system for medications and fluids.
(Gary Landers photo) sorry photo would not copy

At Cincinnati Children's Hospital Medical Center, a $640,000 medication mixing robot will be installed this summer to automatically prepare as many as 600 injections a day.

And this fall at University and Christ hospitals, a three-year program begins to encourage doctors to order medications via computer rather than handwritten slips of paper.

These and other hospitals in Greater Cincinnati are pumping millions of dollars this year into ways to reduce the number of deaths, injuries and treatment problems that can result from medication errors.

"In every hospital, medication errors occur every day," says Sandi King, manager of clinical safety for the TriHealth hospital group.

"Human errors occur because we are human. We get tired. We have too many irons in the fire."

Although no local statistics are available, an estimated 44,000 to 98,000 people a year die from medical errors of all kinds in hospitals nationwide. Of those, medication errors account for about 7,000 deaths a year, according to the Institute of Medicine.

Medication errors also can lead to disabilities, lawsuits and uncounted millions spent on longer hospital stays and emergency treatments.

Since the late 1990s, regulatory agencies, consumers and other interest groups have demanded that hospitals do more to reduce medication errors. In Cincinnati, that pressure has resulted in a wave of spending on new technology.

With so many patients using so many medications, it is easy to imagine that mistakes will be made.

The doctor might misspell the medication. The pharmacist might misread the doctor's instructions. The nurse might punch one too many zeros into the pump that sets the drip rate.

Patients at TriHealth hospitals use more than 550,000 IV bags of medication a year. To replace its lower-tech infusion pumps, the hospital group has turned to San Diego-based Alaris Medical Systems.

The company is one of a handful nationwide that make "smart" infusion pumps that can alert staff if a prescribed dose falls outside pre-programmed high and low dose ranges. Software tracking systems also can send "near miss" reports to hospital administrators.

So TriHealth plans to replace about 625 infusion pumps with the new Alaris system. Not only does the system sound alarms, it can keep track of near-misses for quality improvement reports.


A new approach

Before automation, hospitals relied on a "Swiss cheese" approach to avoid medication errors, says Jack Horn, director of pharmacy for Cincinnati Children's.

While no single human is perfect, errors can be reduced by having multiple people checking that the right medication dose is going to the right patient. Doctors, pharmacists, nurses, technicians, even patients and family members have roles to play - much like layers of Swiss cheese with holes in different places.

"But eventually, the holes line up and an error gets through," Horn said.

The IntelliFill robot system to be used at Children's Hospital is made by Florida-based ForHealth Technologies Inc.

The device is about the size of three refrigerators strapped together and can fill 300 syringes an hour - each with a custom dose and a bar code label routing it to a particular patient.

Such a robot is especially useful in a pediatric hospital because doses have to be adjusted by a patient's weight.

A paperless future?

The Health Alliance of Greater Cincinnati is talking with two vendors about replacing its IV infusion pumps and is considering buying a medication mixing robot, said Dr. Marianne Ivey, director of pharmacy services.

But the most far-reaching project for the Health Alliance will be installing a computer order-entry system to replace handwritten prescription orders from doctors.

The project is expected to take three years to fully install. Small pilot projects involving parts of University and Christ hospitals will begin this fall, Ivey said.

The move would make the Health Alliance the first adult hospital in town to follow Children's Hospital, which launched a similar program in 2002.

Mercy Health Partners plans to spend $25 million in the next five years on error-reducing technology, including about $10 million to install a computer order entry system by the end of 2005, says Jana Deen, regional vice president of patient safety support.

Mercy Health Partners does not plan to buy robotic systems, but smaller projects, including computerized pill dispensing systems, already have been started at all five area Mercy hospitals. Upgrades to infusion pumps also are planned.

"We're already seeing some improvements. We expect to see more," Deen said.

Small hospital challenges

Error-reducing technology ranges widely in Greater Cincinnati. Smaller hospitals with fewer patients have less ability to spread the costs of technology buys.

"We're too small for robots and those kinds of things. But there are a lot of other things you can do to reduce medication errors," says Sylvia Burkey, chief operating officer for McCullough-Hyde Memorial Hospital in Oxford.

For example, the hospital has spent tens of thousands on upgraded infusion pumps and an automated pill-dispensing system.

But Burkey said it could be years before small hospitals can afford to invest in computerized ordering systems.

"Those kinds of things cost a lot of money. And Medicare doesn't increase our reimbursement rates for doing these things," Burkey said.

So instead of relying so much on hardware, smaller hospitals are looking at ways to improve training and organization for staff.

"It's as much about organizational review as about buying a particular piece of technology," she said.

Machines make mistakes too

Anyone familiar with software bugs and power outages knows that machines make mistakes, too.

At Children's Hospital, pharmacy staff already run daily validation tests on medication systems. They expect to make frequent checks on the new syringe-mixing robot as well.

So even though the new machines will help reduce human error, Horn says, hospitals will always need people to check the machines.

The impact of medication errors

• 44,000 to 98,000 people a year die from medical errors in hospitals nationwide.

• 7,000 of those deaths are blamed on medication errors.

• $37.6 billion is spent annually because of medical errors.

• Adverse reactions to drugs injure more than 770,000 people each year in hospitals.

• Patients who have adverse drug reactions were hospitalized an average of 8 to 12 days longer than similar patients.

• Between 28 percent and 95 percent of adverse reactions can be prevented through computerized monitoring systems.

• Computerized medication order entry may prevent an estimated 84 percent of dose, frequency, and route errors.

--Sources: The Institute of Medicine and the Agency for Healthcare Research and Quality, an arm of the U.S. Department of Health and Human Services


---







--------------------------------------------------------------------------------

[Viking65]

By: Raiderman (About 2006)
30 Dec 2005, 11:33 PM EST
Msg. 23353 of 23354
Jump to msg. #
*** Here's what I think for 2006 ***

- 2006 will be OUR year. Finally.
- This partnership with Baxa will produce sales of Valimed units IN THE HUNDREDS in 2006.
- CDEX will penetrate the homeland security market in 2006.
- These last few dips under $1 will be the last chance any of us will have to grab a few extra shares at these bargain basement prices.
- Griffin will be much more successful with CDEX than he was with IPIX.
- We will be thanking Malcolm Philips for his patience, vision and persistence in 2006, because he set all of this up for all of us.
- CDEX will be at least $7.50 by the end of 2006, perhaps a lot higher.

All JMHO. . .but it's almost 2006 and I thought I would look ahead to the coming year. Good luck to us all.

[Viking65]

Happy New Year to the Cdex long and faithful. IMHO Valimed/Cdex will rock in 2006. Yes, it is long awaited. Yes, there are those that don't want it to happen. Yes, there is a group of non shareholders, who are bashing the heck out of this stock for years. Yes, we will be able to laugh in there faces. Yes, there are a few shareholders who sold there shares because of the constant bashing. In my eyes the bashers are criminals. There intent to damage Cdex, and hurt shareholders has been very obvious. The SEC has been notified.

On a positive note, we have Cdex and they don't. Unless they are buying CEXI shares? We know we have many Valimed products, and are on the path to success along with Baxa. What will we have with Homeland Security? With Mr. Griffin, I believe we will have something? All IMHO of course.

What PPS will we achieve? I haven't a clue. Will we have a forward spilt? I haven't a clue. Will we end up on a different exchange? I haven't a clue. Will the next few quarterlies show significant revenue? I haven't a clue. We shall see! I believe we are on to something that is going to be very successful.

[Viking65]

THE DRUG ENFORCEMENT AGENCY (DEA) AND STATE REGULATORY AGENCIES require pharmacies to demonstrate control and security over their controlled- substances inventory, document it accurately, and identify inventory movement or diversion in a timely and retrievable manner. Significant losses of controlled substances must be reported to the DEA, and the agency states that “the loss of a small quantity of controlled substances, repeated over a period of time, may indicate a significant problem.” Always err on the side of caution: If there is a question as to whether a loss is significant, report it to the DEA.With the appropriate technology and systems, maintaining and demonstrating your facility’s control over such substances should be a manageable process.

[Viking65]

Comprehensive Guide to Preventing Controlled Substance Diversion Thank you for your wonderful research CapnMike.

https://www.njshp.org/calendar-events.html

excerpts...
ADMs offer several key reports that can aid in preventing and detecting controlled-substance diversion.

Drugs of Concern
Cocaine (ADD) Hydromorphone
Dextromethorphan (ADD) Ketamine
Fentanyl Oxycodone
Hydrocodone Tramadol


A joint policy between pharmacy and nursing can delineate the handling, administration, and wasting of narcotics and controlled substances.

Handling and Documenting Expired and Wasted Narcotics: Make use of a locked drop box to secure expired and/or wasted narcotics in the pharmacy, and require that narcotic waste be documented and co-signed. Using a “medication pending destruction” report, match waste entries with inventory collected, and then assign at least two pharmacists to verify, document (DEA 41), and destroy the narcotics upon authorization from the Bureau of Drug Enforcement/Control.

= = = = = = =

http://www.valimed.com/impaired_clinician/impairedclinician.htm

http://www.valimed.com/media_center/pr/101305b.htm

http://www.valimed.com/media_center/pr/011405.htm

[pastorll]

Viking65
Thank you for starting this new board. We all need to get the word out to new investors, and you are doing just that.

Larry

[JT_Marlin]

Dont forget about CTGLF!!

[Viking65]

I did not put up all the news. Welcome aboard. I hope this board stays civil. So that investors can learn about the present situation in Valimed.

[baldleooo]

GREAT NEWS !!!!!

Mr. Vike.

It is great to have you starting this board. As you remember I was booted off the other board because I just did not agree with mmmmmmmmm What's his name, sorry I just can't remember. Oh well, it is my best interest.

Keep up the great work, Look forward to chatttin'


Baldleooo

[04greenbay]

Hey Viking65,

I also thank you for the Valimed board. You have already put up a lot of great info for people to start out with that are new to the investment. Have a good day.

Joe

[INET6]

Viking: thanks for the new board.
Let's hope we can keep it informative,without all that three year old (shoulda, coulda, woulda) crying.
Best to all in 2006. It certainly seems like the year to get well again.
Inet6

[Viking65]

CDEX and ValiMed investor information

CDEX Ticker: OTCBB: CEXI

CEXI.ob

( 1 ) CDEX Website

http://www.cdex-inc.com/

( 2 ) ValiMed Website

http://www.valimed.com/

( 3 ) SEC Filing - CDEX Entry into a Material Definitive Agreement

http://www.sec.gov/Archives/edgar/data/1173738/000121465905001670/0001214659-05-001670.txt

( 4 ) BAXA Web Site Info

http://www.baxa.com/NewsAndEvents/press%20releases/CDEX-BaxaAgreement11-10-05.pdf

http://www.baxa.com/NewsAndEvents/press%20releases/ValiMed%20ASHP%20Announcement.pdf

( 5 ) CDEX Patent Applications

20050077476 System and methods for detection and identification of chemical substances

20040155202 Methods and apparatus for molecular species detection, inspection and classification using ultraviolet fluorescence

20030128804 System and method for adapting a software control in an operating environment

http://appft1.uspto.gov/netahtml/PTO/search-bool.html

( 6 ) Waterville Research - CDEX investment information

http://www.watervilleresearch.com/companies/technology/247-1.html

[Viking65]

BAXA site with CDEX news

http://www.baxa.com/NewsAndEvents/press%20releases/ValiMed%20ASHP%20Announcement.pdf

http://www.baxa.com/NewsAndEvents/press%20releases/CDEX-BaxaAgreement11-10-05.pdf


I suspect this next one will be very helpful for the ValiMed hardware users...
http://www.baxa.com/NewsAndEvents/press%20releases/eBug%20Press%20Release.pdf

http://www.baxa.com/NewsAndEvents/Default.asp?ID=3&Item=17

[Viking65]

Maricopa Medical Center Selects CDEX’s ValiMed Technology for End Product Testing

Rockville, MD and Phoenix, AZ – October 12, 2005. CDEX Inc. (OTCBB: CEXI) announces that Maricopa Medical Center in Phoenix, Arizona, has selected the CDEX ValiMed Patient Safety Solution to do end product testing of compounded IV medications in its pharmacy department.

“We are pleased that Maricopa Medical Center has selected the CDEX ValiMed unit as a tool for end product testing,” said Malcolm Philips, CEO and Chairman of the Board for CDEX. “The Maricopa Medical Center offers a great venue to continue to improve our technology. Our list of nationally recognized clients who are using ValiMed continues to grow.”

The ValiMed Patient Safety Solution uses light energy and a library of unique spectral fingerprints to validate IV drugs in solution. The device can validate that the correct drug and correct dose has been added to the medication during the compounding process.

About MIHS:

Maricopa Integrated Health System is headquartered in Phoenix. The cornerstone of the system is Maricopa Medical Center (MMC), a major teaching hospital with a history dating back more than 100 years. Best known for its critical care services, the hospital offers Level 1 trauma and intensive care for adults, babies and children. Two in-patient psychiatric care centers with nearly 200 beds provide services in behavioral medicine. The nation’s second largest burn treatment facility, the Arizona Burn Center, located on the main hospital campus, treats more than 800 patients per year. Eleven family health care centers are located throughout the Valley, providing primary and specialty care ranging from well baby to HIV-AIDS patient services. For more information: www.mihs.org.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jim Griffin or Jerry Blair at 301-881-0080 ([e-mail]).

[Viking65]

CDEX’s ValiMed Unit Selected to Validate Controlled Substance Returns

Rockville, MD – October 13, 2005 – CDEX Inc. (OTCBB: CEXI) announces that its ValiMed Impaired Clinician Solution to validate narcotic returns from an operating room suite has been selected for use by a major academic medical center in the Chicago area. ValiMed provides a simple and effective way to address the Joint Commission on Accreditation of Healthcare Organizations’ standards requiring that all narcotic waste be validated by a pharmacist before disposal.

“The ValiMed system comprises three components: the instrument, a proprietary library of chemical “fingerprints,” and process automation software. The reporting capabilities of the system can help healthcare organizations document compliance with JCAHO standards for controlled substances,” said Malcolm Philips, CDEX’s CEO and Chairman of the Board. “We are excited and honored by the growing number of major medical facilities that are selecting the ValiMed patent pending technology to assist them and we look forward to expanding relationships with each of them in the future.”

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jim Griffin or Jerry Blair at 301-881-0080 ([e-mail]).

[Viking65]

U-M Health System is first in world to use new light-based system to check high-risk medicines

University of Michigan
Pharmacists can verify drug identity & concentration to protect patient safety
July 5, 2005:

ANN ARBOR, MI - Every year, pharmacists at the University of Michigan’s C.S. Mott Children’s Hospital prepare a million doses of medicines for thousands of young and often very ill patients.

And because many of those medicines don’t come in sizes or strengths for use in babies, children and teenagers, the pharmacists and technicians must mix many doses themselves. For some drugs, the smallest error in preparation can be a matter of life and death — so the pharmacy team takes special care to double-check every one.

Now, their team has a new member who adds one more level of safety to the mixing and dispensing of high-risk intravenous drugs like blood thinners and painkillers. But it’s not a person. And it started its career not in a pharmacy, but in bomb detection.

In fact, the new team member is a two-foot-long blue machine called the ValiMed system, which sits on the countertop in the Mott pharmacy. It flashes ultraviolet light into tiny samples of medicines, instantly checking their identity and concentration just before they’re sent to a patient. The system is based on the fact that for most drugs a unique “fingerprint,” called a fluorescence signature, can be detected when they are exposed to ultraviolet (UV) light. Every drug’s fingerprint is different.

The Mott pharmacy team has already added the ValiMed system to their process for preparing 10 commonly used and high-risk drugs.

The U-M Health System is the first medical center in the world to use ValiMed for this purpose. The technology was first developed to detect explosives, and is being used at three other hospitals to verify that narcotic drugs aren’t being diverted.

U-M Pharmacy Services Director Jim Stevenson, Pharm.D., says the ValiMed system eliminates the small amount of potential for human error that remains even with a skilled, trained and experienced pharmacy team.

“No matter what we humans do to check, double-check, and triple-check our work, there’s still that chance for an error to slip through — and with children especially there’s a lot of drug preparation and the risk to the patient from a medication error can be catastrophic,” says Stevenson. “In this case, the technology can assure us that we’re giving the patient the right drug, in the right concentration, just before it goes to the patient’s room. It is the ultimate final check.”

The system is currently in use at Mott Hospital, and another ValiMed system may soon be installed at the main University Hospital that treats adults.

Stevenson and his pharmacy teams have devoted tremendous time and effort to patient safety in recent years, as part of the U-M Health System’s overall push to prevent errors and near-misses, to learn from experience and to ensure high-quality care.

The ValiMed system fits well into that effort, using technology to make absolutely sure that high-risk medications are prepared correctly.

When exposed to ultraviolet (UV) light, every drug has its own characteristic "fingerprint". The ValiMed system checks drug samples against a library of stored fingerprints, acting as a foolproof check before medicines are given to patients.

In fact, the U-M pharmacy team has worked with ValiMed staff in recent months to set the standards that the machine uses to identify drugs. Every time it scans a one-milliliter sample of a medication, the machine compares the sample’s fluorescence “fingerprint” with a library of standard fingerprints in its memory. U-M pharmacists worked with the manufacturers of ValiMed to create that library for high risk medications, and performed pilot testing of the system before implementing it at Mott.

The current reference library includes ten commonly used intravenous drugs that need to be mixed specially for children and carry an especially high risk if they are delivered in the wrong concentration or to the wrong patient.

They include insulin, used to bring down blood sugar; heparin, used to thin blood; epinephrine, used to support blood pressure and cardiac function; narcotics such as morphine that reduce pain; and antibiotics such as vancomycin that can tame infections but can also be toxic if an incorrect dose is given.

Often, Stevenson says, pharmacists will make a batch of these drugs to dispense to many patients, using bulk medications and IV solution to dilute them so they can be delivered intravenously. Then, for each patient who needs the drug, the pharmacist will fill an IV bag or syringe for the nurse to administer. This means that if a mistake is made in creating the batch, many patients can suffer.

With ValiMed in place, the Mott pharmacists have incorporated a new step into their routine: they draw a tiny sample of the finished IV product, place it in a small square test tube that plugs into the top of the ValiMed machine, wait approximately 30 seconds, and read the machine’s display. It tells them if the fluorescence fingerprint from the sample matches the fingerprint for the same drug and concentration from the library.

The Mott team plans to develop more drugs in the ValiMed reference library, and to perfect the process for using the machine as part of their routine procedure. Other possible future uses include validating the identity and dose of chemotherapy drugs used in cancer patients.

“We know that medication errors are already extremely rare at Mott, and anywhere at U-M, but our goal is to not have any at all,” says Stevenson. “This system will give us, and our patients and their parents, a little more peace of mind that we’re doing all we can to prevent errors. This is part of our mission to be a leader in medication and patient safety.”

Stevenson credits Darrell Campbell, M.D., chief of staff for the U-M Hospitals & Health Centers, and others in the U-M Office of Clinical Affairs, for providing initial funding for the system. He also notes the role of Mott Pharmacy supervisor Denise Glenn, BS Pharm., Clinical Coordinator Deborah Pasko, Pharm.D., and pharmacist Hanna Phan, Pharm.D., for their role in implementing the system.

Written by Kara Gavin

Source:
http://www.med.umich.edu/opm/newspage/2005/mottpharm.htm

[Viking65]

University of Maryland Medical Center Partners with CDEX to Implement Medication Validation Solution

CDEX’s ValiMed System Chosen by UMMS to Verify Compounded Medications and Doses, Validate Narcotic Returns, and Identify Counterfeit Pharmaceuticals
Rockville, MD and Baltimore, MD– November 29, 2005 –The University of Maryland Medical Center has selected the CDEX (OTCBB: CEXI) ValiMed system to perform end product testing of compounded intravenous medications in its pharmacy departments, and validation of returned narcotics in its operating room suites and nursing units. The CDEX ValiMed medication verification system was developed to give clinicians a quick, cost effective, and simple tool to further ensure medication safety by verifying medications are correctly compounded. The University of Maryland Medical Center (UMMC) is part of a private, not-for-profit organization that includes six hospitals and has more than 11,000 employees. The system provides a full range of primary and specialty care to people throughout Maryland and the Mid-Atlantic region. ValiMed will be installed at the University of Maryland Medical Center, a 655-bed teaching hospital.

In a process that takes only seconds, ValiMed uses patent pending technology to validate compounded doses of high-risk medications prior to dispensing. The solution creates an added level of safety in the medication dispensing process, and is also used to validate narcotic returns as well as identify counterfeit medications.

“We are focused on patient safety at UMMC, and the CDEX ValiMed product offers us an additional opportunity to validate the end products being dispensed from the pharmacy and to validate returned narcotics, ” said Marc Summerfield, Director of Pharmacy at UMMC. “With ValiMed, we will have an added level of safety on certain products that we dispense every day, and added cost-effective audit capabilities for our controlled substances compliance initiatives.”

“As the list of nationally-recognized healthcare providers using the ValiMed solution continues to grow, CDEX is particularly pleased that the University of Maryland Medical Center, a world-class hospital located in the same region where CDEX is headquartered, has selected this innovative, proven system for end-product medication testing and return narcotic validation,” said Malcolm Philips, CEO and Chairman of the Board for CDEX.”

The CDEX ValiMed solution uses light energy and a library of unique spectral fingerprints to validate drugs in solution. The device validates that the correct drugs in the correct amounts have been added to the dose during the compounding process.

About The University of Maryland Medical Center (UMMC)
For more information, visit www.umm.edu.

About CDEX, Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jim Griffin or Jerry Blair at 301-881-0080 ([e-mail]).

[Viking65]

CDEX to Demonstrate Validation of Flu Vaccine and Flu Medications at The American Society of Health Systems Pharmacists (ASHP) MidYear Clinical Meeting December 4-8

Rockville, MD – November 14, 2005 – CDEX Inc. (OTCBB: CEXI), developer of the ValiMed™ Medication Validation System and other innovative substance detection and verification systems, announces its participation in the 40th MidYear Clinical Meeting of the American Society of Health Systems Pharmacists (ASHP) December 4-8, 2005 in Las Vegas. At ASHP, CDEX will be demonstrating its ValiMed Medication Validation System, and demonstrating how CDEX technology can be utilized to validate authentic influenza vaccine and Tamiflu medication. Counterfeiting of influenza remedies and many other medications and vaccines is a growing problem.

In addition to anti-counterfeiting capabilities, CDEX’s ValiMed System is being deployed by health-system pharmacists nationwide to verify compounded medications, correct dosages, and to validate narcotics returns.

CDEX will be located at ASHP Booth 1021 to demonstrate ValiMed’s validation capabilities. Jim Griffin, COO, and Jerry Blair, VP of Business Operations, will be available for interviews.

In addition to demonstrations at the CDEX booth, the ValiMed solution will be highlighted at the following presentations at ASHP:

Presentation: Wednesday, 12/7/2005, 3:00 p.m. Use of Spectroscopy to Enhance Safety in IV Compounding, James G. Stevenson, Pharm.D., Director of Pharmacy Services, University of Michigan Health System, Ann Arbor

Poster: Monday, 12/5/2005, 2:00 p.m. Board 135, Improving medication safety: use of spectral medication validation in high risk intravenous medication (IV) compounding in a pediatric hospital pharmacy, Hanna Phan, Deborah Pasko, John F Mitchell, Denise K. Glenn, Diane S. Shoemaker, James G. Stevenson

About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication; detection of counterfeit or sub-par products for brand protection; and quality assurance inspection of materials). CDEX is headquartered in Rockville, Maryland and has its primary research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.

[Viking65]

CDEX and Baxa Sign Distribution Agreement

Rockville, MD – November 10, 2005 – CDEX Inc. (OTCBB: CEXI), developer of the ValiMed™ Medication Validation System and other innovative substance detection and verification systems, announces a strategic distribution agreement with Baxa Corporation, a leader in developing systems for preparing, handling, packaging, and administering liquid medications. Baxa will be the exclusive distributor of the CDEX ValiMed System for healthcare organizations in the United States and Canada.

The ValiMed System offers clinicians a simple and cost-effective tool to ensure medication safety by verifying that medications are correctly compounded. Its patent-pending technology identifies the medication and strength to validate compounded doses of high risk medications prior to dispensing. The ValiMed device verifies medications in seconds and provides an added level of safety in the medication dispensing process. The ValiMed System also validates narcotic returns.

“The ValiMed sales required under the Baxa contract, coupled with existing sales and rentals, will solidify the CDEX presence in the medical market and more completely validate our technology for other markets,” said Malcolm Philips, CDEX CEO and Chairman. “With Baxa’s award-winning customer service and sales teams, we have moved toward that goal in the medical marketplace.”

The agreement calls for purchase of a fixed number of ValiMed units by Baxa for two years, as well as goals that must be met in order to maintain the Baxa exclusive distribution rights.

“The ValiMed System fits with Baxa Corporation's mission to offer our customers innovative fluid medication devices that improve operations and increase medication safety. ValiMed is a great addition to our product line,” said Greg Baldwin, Baxa Chairman and CEO.

CDEX’s mission is to develop innovative technologies that assist in solving real world problems, then work with industry leaders to bring those products to market. For more than 30 years, Baxa Corporation has focused on developing systems and devices that streamline pharmacy operations, enhancing patient safety and improving efficiency.

About Baxa Corporation
Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging, and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternative-site pharmacies. Privately held, Baxa Corporation has subsidiaries and offices in Canada, the United Kingdom and Denmark, and distribution partners worldwide. Further information is available at www.baxa.com.

About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication; detection of counterfeit or sub-par products for brand protection; and quality assurance inspection of materials). CDEX is headquartered in Rockville, Maryland and has its primary research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com.

[Viking65]

BAXA and CDEX Announce Strategic Alignment

Englewood, CO and Rockville, MD – November 2, 2005 – Baxa Corporation and CDEX Inc. (OTCBB: CEXI) announced today a $1.5 million equity investment by Baxa in CDEX. In addition, the investment agreement provides a vehicle for an additional optional Baxa investment of up to $1 million over the next nine months and an offer to Baxa of a seat on the CDEX Board of Directors. (For additional details, see the 8K filed with the SEC.)

“We are pleased that Baxa has invested in CDEX and view this decision as a first step toward strategic alignment between Baxa and CDEX” states Malcolm Philips, CDEX’s Chairman and CEO. “Baxa is a well-respected name in the medical community and its investment in CDEX will facilitate faster expansion into that and other markets.”

“We looked closely at CDEX and found a technological and cultural alignment with our business and values,” said Greg Baldwin, Baxa’s Chairman and CEO. “This investment marks our confidence in CDEX and its ability to continue to develop innovative products that solve real world problems inside and outside the medical market. We welcome the opportunity to work with CDEX in the future.”

About Baxa Corporation

Celebrating 30 years of business in 2005, Baxa Corporation is a Denver-based manufacturer of medical devices and systems for preparing, handling, packaging and administering liquid medications. The company manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada, the United Kingdom, Denmark, and Germany and distribution partners worldwide. Further information is available at www.baxa.com.

Marian Robinson, Vice President, Marketing
800.567.2292 ext. 2157 or 303.617.2157
Email: [e-mail]

Maggie Chamberlin Holben, APR
Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: [e-mail]

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jerry Blair at 301.881.0080 ([e-mail]).